Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)

11 de septiembre de 2026 actualizado por: Gilead Sciences

Un estudio de fase 3, doble ciego, multicéntrico, aleatorizado para evaluar la eficacia y la seguridad del lenacapavir subcutáneo dos veces al año de acción prolongada para la profilaxis previa a la exposición al VIH en hombres cisgénero, mujeres transgénero, hombres transgénero y personas no binarias de género ≥ 16 años de Edad que tienen relaciones sexuales con parejas masculinas y corren el riesgo de contraer la infección por el VIH

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.

The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

3292

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Buenos Aires, Argentina, 1072
        • Hospital General de Agudos JM Ramos Mejia
      • Buenos Aires, Argentina, B7600
        • Instituto de Investigaciones Clinicas Mar del Plata
      • Buenos Aires, Argentina, 1202
        • Fundacion Huesped
      • Belo Horizonte - MG, Brasil, 30130-100
        • Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
      • Canela-Salvador, Brasil, 40110-060
        • Fundação Bahiana de Infectologia
      • Manauas, Brasil, 69040-000
        • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
      • Nova Iguaçu, Brasil, 26030-380
        • Hospital General de Nova Iguaçu - HGNI
      • Porto Alegre, Brasil, RS 91350 200
        • Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
      • Rio de Janeiro, Brasil, 21040-360
        • Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
      • São Paulo, Brasil, 01246-903
        • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
      • São Paulo, Brasil, 04121-000
        • Centro de Referência e Treinamento DST/AIDS
      • São Paulo, Brasil, 06519-332
        • Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • UAB Sexual Health Research Clinic
    • California
      • Loma Linda, California, Estados Unidos, 92354
        • Loma Linda University Clinical Trial Center Clinic
      • Los Angeles, California, Estados Unidos, 90069
        • Mills Clinical Research
      • Los Angeles, California, Estados Unidos, 90036
        • Ruane Clinical Research Group Inc.
      • Los Angeles, California, Estados Unidos, 90038
        • UCLA CBAM Vine Street Clinic
      • Los Angeles, California, Estados Unidos, 90059
        • Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
      • Los Angeles, California, Estados Unidos, 90502
        • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      • Palm Springs, California, Estados Unidos, 92262
        • BIOS Clinical Research
      • San Diego, California, Estados Unidos, 92103
        • UCSD Anti Viral Research Center
      • San Francisco, California, Estados Unidos, 94102
        • Optimus Medical Group
      • San Francisco, California, Estados Unidos, 94102
        • Bridge HIV at the San Francisco Department of Public Health
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • University of Colorado Clinical and Translational Research Centers (CTRC)
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Yale University, School of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20009
        • Whitman-Walker Institute Inc.
      • Washington D.C., District of Columbia, Estados Unidos, 20017
        • Washington Health Institute
    • Florida
      • Fort Lauderdale, Florida, Estados Unidos, 33308
        • Therafirst Medical Center
      • Fort Lauderdale, Florida, Estados Unidos, 33316
        • Gary Richmond, MD, PA
      • Ft. Pierce, Florida, Estados Unidos, 34982
        • Midway Immunology & Research Center, LLC
      • Jacksonville, Florida, Estados Unidos, 32207
        • CAN Community Health Clinic
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
      • Miami Gardens, Florida, Estados Unidos, 33055
        • CAN Community Health
      • Orlando, Florida, Estados Unidos, 32803
        • Orlando Immunology Center
      • Sarasota, Florida, Estados Unidos, 34237
        • CAN Community Health
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303
        • Emory University
      • Atlanta, Georgia, Estados Unidos, 30308
        • Emory University Hospital Midtown Infectious Disease Clinic
      • Atlanta, Georgia, Estados Unidos, 30030
        • The Hope Clinic at Emory University
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60613
        • Howard Brown Health Center
      • Chicago, Illinois, Estados Unidos, 60612
        • RMR Core Center
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University Infectious Diseases Research
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, Estados Unidos, 40241
        • Norton Infectious Disease Specialists
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70119
        • LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Johns Hopkins University School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • The Fenway Institute
    • Michigan
      • Berkley, Michigan, Estados Unidos, 48072
        • Be Well Medical Center
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Hospital
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39202
        • Open Arms Healthcare Center
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64111
        • KC CARE Health Center
    • New Jersey
      • Newark, New Jersey, Estados Unidos, 07102
        • St. Michael's Medical Center
      • Somers Point, New Jersey, Estados Unidos, 08244
        • South Jersey Infectious Disease
    • New York
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
      • Greensboro, North Carolina, Estados Unidos, 27401
        • Cone Health/Regional Center for Infectious Disease Research Center
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Wake Forest University Health Sciences
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45267
        • University of Cincinnati
      • Columbus, Ohio, Estados Unidos, 43210
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Penn Prevention Unit
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina, Infectious Disease Clinic
      • Columbia, South Carolina, Estados Unidos, 29203
        • Prisma Health-Midlands Clinical Research Unit
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Internal Medicine Clinic
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38105
        • St Jude Children's Research Hospital
      • Memphis, Tennessee, Estados Unidos, 38103
        • Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
      • Nashville, Tennessee, Estados Unidos, 37208
        • Meharry Medical College Clinical and Transitional Research Center
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • Central Texas Clinical Research
      • El Paso, Texas, Estados Unidos, 79915
        • Centro San Vincente
      • Houston, Texas, Estados Unidos, 77098
        • The Crofoot Research Center, INC
      • Houston, Texas, Estados Unidos, 77009
        • UT Health Science Center at Houston
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • Ofiice of Dr. Peter Shalit, MD
      • Guadalajara C.P., México, 44160
        • Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
      • Barranco, Perú, 15063
        • Asociacion Civil Impacta Salud y Educacion - Sede Barranco
      • Callao, Perú, 7006
        • Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
      • Iquitos, Perú
        • Asociacion Civil Selva Amazonica
      • Lima, Perú, 15001
        • Via Libre
      • Lima, Perú, 15088
        • Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
    • PR
      • San Juan, PR, Puerto Rico, 00717
        • Ararat Research Center
      • San Juan, PR, Puerto Rico, 00909
        • Centro Ararat- San Juan
      • Cape Town, Sudáfrica, 7925
        • Desmond Tutu Health Foundation
      • Johannesburg, Sudáfrica, 2038
        • Wits Reproductive Health and HIV Institute (Wits RHI)
      • Pretoria, Sudáfrica, 87
        • The Aurum Institute: Pretoria Clinical Research Centre
      • Soshanguvhe, Sudáfrica, 0152
        • Setshaba Research Centre
      • Tembisa, Sudáfrica, 1632
        • The Aurum Institute Tembisa CRC, Clinic 4
      • Vincent, Sudáfrica, 5217
        • FPD-DTHF Ndevana Commuity Research Site
      • Bangkok, Tailandia, 10330
        • King Chulalongkorn Memorial Hospital
      • Bangkok, Tailandia, 10400
        • Ramathibodi Hospital, Mahidol University
      • Bangkok, Tailandia, 10330
        • Institute of HIV Research and Innovation
      • Bangkok, Tailandia, 10330
        • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
      • Chiang Mai, Tailandia, 50200
        • Research Institute for Health Sciences, Chiang Mai University
      • Khon Kaen, Tailandia, 40002
        • Srinagarind Hospital, Khon Kaen University
      • Nonthaburi, Tailandia, 11000
        • Bamrasnaradura Infectious Disease Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

16 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

Incidence Phase

  • CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.

  • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.

  • Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:

    • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
    • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
    • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

  • Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

Incidence Phase

  • Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
  • Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

  • Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks
  • Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily
  • Oral LEN 600 mg on Days 1 and 2

Participants will receive oral LEN if SC injections are not available.

Tablets administered orally without regard to food

Otros nombres:
  • GS-6207

Administered via SC injections

Otros nombres:
  • GS-6207; Yeztugo

Tablets administered orally

Experimental: Randomized Blinded Phase: Placebo LEN + F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • SC LEN placebo every 26 weeks
  • Oral F/TDF 200/300 mg once daily
  • PTM Oral LEN on Days 1 and 2

Participants will receive oral LEN placebo if SC injections are not available.

Tablets administered orally

Otros nombres:
  • Truvada®

Administered via SC injections

Tablets administered orally

Experimental: LEN Open-Label Extension (OLE) Phase

Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase.

Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days).

Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2.

All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first.

After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit.

Tablets administered orally without regard to food

Otros nombres:
  • GS-6207

Administered via SC injections

Otros nombres:
  • GS-6207; Yeztugo
Experimental: Pharmacokinetic (PK) Tail Phase

Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days).

Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit.

Tablets administered orally

Otros nombres:
  • Truvada®

F/TAF tablets administered orally once daily

Otros nombres:
  • Descubrir

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
Periodo de tiempo: Incidence Phase Screening Visit (Day 1)

bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood.

HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:

  • Positive HIV-1/2 differentiation Ab, OR
  • Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR
  • HIV-1 RNA quantitative test ≥200 copies/mL.
Incidence Phase Screening Visit (Day 1)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
Periodo de tiempo: Up to 149 weeks

HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

Up to 149 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
Periodo de tiempo: Up to 149 weeks

HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

Up to 149 weeks
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
Periodo de tiempo: Up to 149 weeks

A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

Up to 149 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Periodo de tiempo: First dose date up to 184 weeks

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.

First dose date up to 184 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
Periodo de tiempo: First dose date up to 184 weeks

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

First dose date up to 184 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Gilead Study Director, Gilead Sciences

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de junio de 2021

Finalización primaria (Actual)

21 de agosto de 2024

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

28 de mayo de 2021

Primero enviado que cumplió con los criterios de control de calidad

11 de junio de 2021

Publicado por primera vez (Actual)

14 de junio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir